When did PARATEK PHARMACEUTICALS INC (PRTK) report earnings last quarter?
PARATEK PHARMACEUTICALS INC (PRTK) last reported earnings on 8/3/2023.
NASDAQ:PRTK • US6993743029
Past quarterly earnings results for PARATEK PHARMACEUTICALS INC (PRTK), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q2 2023 | -0.25 | -0.32 | 21.78% | 24.24% | 39.993M | 34.527M | 15.83% | 34.94% |
| Q1 2023 | -0.35 | -0.43 | 18.30% | - | 31.236M | 30.685M | 1.80% | 25.64% |
| Q4 2022 | -0.12 | 0.10 | -226.05% | 81.82% | 75.557M | 64.724M | 16.74% | 137.62% |
| Q3 2022 | -0.38 | -0.30 | -28.47% | -2.70% | 30.213M | 34.876M | -13.37% | 23.59% |
| Q2 2022 | -0.33 | -0.34 | 3.90% | -265.00% | 29.637M | 29.75M | -0.38% | -48.45% |
| Q1 2022 | -0.35 | -0.36 | 1.96% | 10.26% | 24.861M | 27.693M | -10.23% | 51.31% |
| Q4 2021 | -0.66 | -0.42 | -56.86% | -10.00% | 31.797M | 36.05M | -11.80% | 98.48% |
| Q3 2021 | -0.37 | -0.46 | 19.39% | 19.57% | 24.447M | 24.293M | 0.63% | 78.97% |
| Q2 2021 | 0.20 | 0.32 | -37.75% | 137.74% | 57.492M | 62.207M | -7.58% | 516.21% |
| Q1 2021 | -0.39 | -0.39 | -0.09% | 40.91% | 16.43M | 29.293M | -43.91% | 107.45% |
| Q4 2020 | -0.60 | -0.05 | -1,207.19% | - | 16.02M | 34.718M | -53.86% | - |
| Q3 2020 | -0.46 | -0.62 | 26.07% | - | 13.66M | 12.135M | 12.57% | - |
| Q2 2020 | -0.53 | -0.06 | -731.37% | - | 9.33M | 38.789M | -75.95% | - |
| Q1 2020 | -0.66 | -0.82 | 19.37% | - | 7.92M | 7.613M | 4.03% | - |
Notes
PARATEK PHARMACEUTICALS INC (PRTK) last reported earnings on 8/3/2023.
PARATEK PHARMACEUTICALS INC (PRTK) beat EPS estimates and beat revenue estimates in the most recent quarter.
In the last 4 quarters, PARATEK PHARMACEUTICALS INC (PRTK) has beaten EPS estimates in 2 out of 4 releases.